Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.

ABSTRACT:

Background

Incident heart failure (HF) is increased in persons with human immunodeficiency virus (PHIV). Protease inhibitors (PIs) are associated with adverse cardiac remodeling and vascular events; however, there are no data on the use of PIs in PHIV with HF.

Objectives

This study sought to compare characteristics, cardiac structure, and outcomes in PHIV with HF who were receiving PI-based versus non-PI (NPI) therapy.

Methods

This was a retrospective single-center study of all 394 antiretroviral therapy-treated PHIV who were hospitalized with HF in 2011, stratified by PI and NPI. The primary outcome was cardiovascular (CV) mortality, and the secondary outcome was 30-day HF readmission rate.

Results

Of the 394 PHIV with HF (47% female, mean age 60 ± 9.5 years,

SUBMITTER: Alvi RM 

PROVIDER: S-EPMC6202063 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature